These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6852325)

  • 1. Possible dosage regimens for topical steroids, assessed by vasoconstrictor assays using multiple applications.
    Woodford R; Haigh JM; Barry BW
    Dermatologica; 1983; 166(3):136-40. PubMed ID: 6852325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasoconstrictor activities and bio-availabilities of seven proprietary corticosteroid creams assessed using a non-occluded multiple dosage regimen; clinical implications.
    Barry BW; Woodford R
    Br J Dermatol; 1977 Nov; 97(5):555-60. PubMed ID: 588468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onset of the vasoconstrictor effect of diflucortolone valerate, betamethasone valerate, and fluocinolone acetonide ointments applied for varying periods under occlusive dressings.
    Szadurski J; Renz F; Gasser D
    Dermatologica; 1976; 153(4):236-42. PubMed ID: 1017533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release of betamethasone 17-valerate from extemporaneous dilutions of a proprietary topical cream.
    Magnus AD; Haigh JM; Kanfer I
    Dermatologica; 1981; 163(4):331-7. PubMed ID: 7308554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of systemic and topical effects of topical steroid application through the comparison of two application schedules.
    Fukaya Y; Masutani M; Koyama Y; Takahashi H; Ueda H
    J Dermatol; 1990 Jan; 17(1):28-33. PubMed ID: 2329214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay of topical corticosteroids. Efficacy of suppression of experimental Rhus dermatitis in humans.
    Kaidbey KH; Kligman AM
    Arch Dermatol; 1976 Jun; 112(6):808-13. PubMed ID: 133636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of some variables affecting the blanching activity of betamethasone 17-valerate cream.
    Magnus AD; Haigh JM; Kanfer I
    Dermatologica; 1980; 160(5):321-7. PubMed ID: 7364141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of serial dilution of betamethasone-17-valerate on blanching potential and chemical stability.
    Ryatt KS; Cotterill JA; Mehta A
    J Clin Hosp Pharm; 1983 Jun; 8(2):143-5. PubMed ID: 6875011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemphigoid and pemphigus foliaceus successfully treated with topical corticosteroids.
    Muramatsu T; Iida T; Shirai T
    J Dermatol; 1996 Oct; 23(10):683-8. PubMed ID: 8973033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The stability and blanching efficacy of betamethasone-17-valerate in emulsifying ointment.
    Ryatt KS; Feather JW; Mehta A; Dawson JB; Cotterill JA; Swallow R
    Br J Dermatol; 1982 Jul; 107(1):71-6. PubMed ID: 7104209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once daily application of diflorasone diacetate ointment compared with betamethasone valerate ointment twice daily in patients with eczematous dermatoses.
    Hersle K; Mobacken H
    J Int Med Res; 1982; 10(6):423-5. PubMed ID: 7152081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind comparison of 1% hydrocortisone plus 10% urea ('Alphaderm') and 0.1% betamethasone 17-valerate in the treatment of non-infective inflammatory dermatoses.
    Khan SA; Williamson DM
    Curr Med Res Opin; 1977-1978; 5(4):354-8. PubMed ID: 343995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans. Inhibition of UV-B-induced inflammation monitored by laser Doppler blood flowmetry.
    Bjerring P
    Skin Pharmacol; 1993; 6(3):187-92. PubMed ID: 8274288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of the vasoconstrictor assay and clinical activity in psoriasis.
    Woodford R
    Arch Dermatol; 1986 Dec; 122(12):1355. PubMed ID: 3789765
    [No Abstract]   [Full Text] [Related]  

  • 15. The influence of corticosteroids and topical indomethacin on sunburn erythema.
    Kaidbey KH; Kurban AK
    J Invest Dermatol; 1976 Mar; 66(3):153-6. PubMed ID: 1249444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of bioavailability of topical steroids: non-occluded penetration enhancers under thermodynamic control.
    Bennett SL; Barry BW; Woodford R
    J Pharm Pharmacol; 1985 May; 37(5):298-304. PubMed ID: 2862236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay.
    Pershing LK; Silver BS; Krueger GG; Shah VP; Skelley JP
    Pharm Res; 1992 Jan; 9(1):45-51. PubMed ID: 1589409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasoconstrictor activities of some novel synthetic steroids in alcoholic solution.
    Barry BW; Brace AR
    J Invest Dermatol; 1975 Jun; 64(6):418-22. PubMed ID: 1141715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Testing the loss of efficacy (tachyphylaxis) during external steroid application].
    Koch EM; Jurgovsky E
    Hautarzt; 1985 Mar; 36(3):146-9. PubMed ID: 3997512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of different areas of the flexor aspect of the human forearm to corticosteroid-induced skin blanching.
    Meyer E; Smith EW; Haigh JM
    Br J Dermatol; 1992 Oct; 127(4):379-81. PubMed ID: 1419758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.